#1 Clinical Trials Search in Europe

Leflunomide

Leflunomide, also known by the brand name Arava, is a medication that has been the subject of several clinical trials exploring its potential in treating various conditions. Originally approved for rheumatoid arthritis, researchers are now investigating its effectiveness in other areas such as cancer, graft-versus-host disease, and even COVID-19. This article summarizes key findings from recent clinical trials using leflunomide, providing insights into its potential new applications and safety profile.

Table of Contents

What is Leflunomide?

Leflunomide is a medication primarily used to treat certain autoimmune conditions. It’s known by several names, including its brand name Arava and the research code SU101[1]. Leflunomide belongs to a class of drugs called disease-modifying antirheumatic drugs (DMARDs), which work by reducing inflammation and slowing down the progression of certain diseases[2].

Conditions Treated with Leflunomide

Leflunomide is approved and used for treating several conditions:

  • Rheumatoid Arthritis: This is a chronic inflammatory disorder affecting the joints[2].
  • Psoriatic Arthritis: A form of arthritis that affects some people with psoriasis[3].
  • Juvenile Idiopathic Arthritis: A type of arthritis that affects children[4].

Additionally, researchers are exploring its potential use in other conditions, which we’ll discuss later in this article.

How Leflunomide Works

Leflunomide works by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH). This enzyme is important for the rapid growth of certain cells, including some that are involved in inflammation. By blocking this enzyme, leflunomide can help reduce inflammation and slow down the progression of diseases like rheumatoid arthritis[5].

In the body, leflunomide is converted to its active form called teriflunomide. This active form is responsible for the therapeutic effects of the medication[6].

How Leflunomide is Administered

Leflunomide is typically taken orally (by mouth) as a tablet. The dosage can vary depending on the condition being treated and the patient’s response to the medication. Here are some common dosing regimens:

  • For adults with rheumatoid arthritis: Usually started with a loading dose of 100 mg daily for 3 days, followed by a maintenance dose of 20 mg daily[7].
  • For children with juvenile idiopathic arthritis: The dose is based on the child’s weight. For example, children weighing less than 20 kg might take 10 mg every other day, while those weighing more than 40 kg might take 20 mg daily[4].

It’s important to note that your doctor will determine the right dosage for you based on your specific condition and needs.

Potential Side Effects

Like all medications, leflunomide can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Headache
  • Rash
  • Elevated liver enzymes

More serious side effects can occur, though they are less common. These may include liver problems, blood disorders, and an increased risk of infections. Your doctor will monitor you closely while you’re taking leflunomide to watch for any potential side effects[3].

Ongoing Research and Potential New Uses

Researchers are exploring the potential use of leflunomide in several other conditions:

  • Cancer Treatment: Studies are investigating leflunomide’s potential in treating certain types of cancer, including triple-negative breast cancer and lymphomas[5][1].
  • Chronic Graft Versus Host Disease: This is a complication that can occur after bone marrow transplantation[6].
  • COVID-19: Some researchers have explored leflunomide’s potential antiviral effects against the virus that causes COVID-19[8].
  • Henoch-Schonlein Purpura: A condition that involves swelling of small blood vessels and can cause a skin rash and other symptoms[9].

It’s important to note that these are areas of ongoing research, and leflunomide is not yet approved for treating these conditions.

Precautions and Considerations

Leflunomide requires careful monitoring by your healthcare provider. Here are some important considerations:

  • Liver Function: Regular blood tests are needed to monitor liver function while taking leflunomide[3].
  • Pregnancy: Leflunomide can cause harm to an unborn baby. Women of childbearing age should use effective contraception while taking this medication and for some time after stopping it[3].
  • Infections: Leflunomide can increase the risk of infections. Tell your doctor if you develop signs of an infection while taking this medication[6].
  • Vaccinations: Live vaccines should be avoided while taking leflunomide. Discuss any planned vaccinations with your doctor.

Always take leflunomide exactly as prescribed by your doctor, and don’t hesitate to ask questions or report any side effects you experience.

Condition Trial Phase Key Findings/Objectives
Rheumatoid Arthritis Post-authorization safety study Assessing healthcare professionals’ awareness and knowledge of risk minimization measures for leflunomide
Triple-negative breast cancer Phase I/II Determining safety, tolerability, and maximum tolerated dose; evaluating efficacy in TNBC patients
CD30+ lymphoproliferative disorders Pilot trial Evaluating overall response rate and toxicity profile in relapsed/refractory cases
Chronic graft-versus-host disease Phase I Assessing safety, tolerability, and preliminary efficacy in steroid-dependent cGVHD
COVID-19 Tolerability study Examining tolerability of high-dose leflunomide in mild COVID-19 outpatients
PTEN-altered advanced solid tumors Phase Ia/Ib Determining safety, tolerability, and preliminary clinical activity in PTEN-null malignancies
Juvenile idiopathic arthritis Randomized controlled trial Assessing efficacy in methotrexate-refractory cases using ACR Pediatric response criteria
Henoch-Schonlein purpura Prospective, one-arm trial Evaluating safety and effectiveness in refractory skin HSP in children

FAQ

  • What is leflunomide and how does it work? Leflunomide is a medication originally approved for treating rheumatoid arthritis. It works by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH), which is involved in the production of immune cells. This action helps reduce inflammation and modulate the immune system.
  • What new conditions are being studied for leflunomide treatment? Recent clinical trials are exploring leflunomide's potential in treating various cancers (including breast cancer and lymphomas), chronic graft-versus-host disease, COVID-19, and certain pediatric conditions like juvenile idiopathic arthritis and Henoch-Schonlein purpura.
  • How is leflunomide administered in clinical trials? In most trials, leflunomide is given orally as a daily tablet. The dosage can vary depending on the condition being treated and the patient's weight. Some studies use a loading dose followed by a lower maintenance dose.
  • What are some potential side effects of leflunomide? Common side effects may include gastrointestinal issues, liver function changes, and increased risk of infections. Clinical trials closely monitor patients for these and other potential adverse effects to establish the safety profile of leflunomide for new indications.
  • How long do leflunomide clinical trials typically last? The duration of leflunomide trials varies widely depending on the condition being studied and the trial phase. Some trials last for a few months, while others may continue for a year or more, often with additional follow-up periods to assess long-term outcomes and safety.

Ongoing Clinical Trials on Leflunomide

  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Italy The Netherlands Norway Spain +1

  • Study on Leflunomide and Hydroxychloroquine for Patients with Primary Sjögren’s Syndrome

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland

Glossary

  • Leflunomide: An immunomodulatory medication originally approved for rheumatoid arthritis, now being studied for various other conditions. It works by inhibiting an enzyme involved in immune cell production.
  • Clinical trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • DHODH: Dihydroorotate dehydrogenase, an enzyme involved in the production of immune cells that is inhibited by leflunomide.
  • Graft-versus-host disease (GVHD): A complication that can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient's body.
  • Triple-negative breast cancer (TNBC): A type of breast cancer that lacks expression of estrogen receptor, progesterone receptor, and HER2 protein, making it more difficult to treat with hormone therapies.
  • Maximum tolerated dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects in a clinical trial.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dose or require a dose reduction in a clinical trial.
  • Juvenile idiopathic arthritis: A type of arthritis that affects children, causing joint pain and inflammation.

References

  1. https://clinicaltrials.gov/study/NCT04463615
  2. https://clinicaltrials.gov/study/NCT00451971
  3. https://clinicaltrials.gov/study/NCT06714461
  4. https://clinicaltrials.gov/study/NCT02024334
  5. https://clinicaltrials.gov/study/NCT03709446
  6. https://clinicaltrials.gov/study/NCT04212416
  7. https://clinicaltrials.gov/study/NCT04997993
  8. https://clinicaltrials.gov/study/NCT04361214
  9. https://clinicaltrials.gov/study/NCT05937880